Q-omics provides the consensus-scored SPART-AS1 profile across patient tissues and cancer cell-line models. SPART-AS1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPART-AS1 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, SPART-AS1 RNA expression shows 17,450 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where SPART-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPART-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPART-AS1 survival associations across molecular data types. SPART-AS1 RNA expression shows survival associations in the most cancer types (23), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPART-AS1 RNA expression–survival associations across cancer types. High SPART-AS1 expression shows unfavorable associations in KIRC, COAD and SKCM, but favorable associations in KIRP, LAML and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SPART-AS1 RNA expression.
This table summarizes SPART-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SPART-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPART-AS1 shows lower tumor expression in KICH, BRCA, THCA, LUAD, LUSC and UCEC. The KICH box plot shows higher SPART-AS1 RNA expression in normal versus tumor tissue (log2 FC = −1.268, t-test p < 0.001).
This table shows molecular features associated with SPART-AS1 in patient tissues and cancer cell lines. In patient samples, SPART-AS1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
